Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term drusen study.

D Sarraf1, T Gin, F Yu

  • 1VA Greater Los Angeles Healthcare System, Ophthalmology Section, and the Jules Stein Eye Institute, UCLA School of Medicine, California, USA.

Retina (Philadelphia, Pa.)
|December 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Why the macula?

Eye (London, England)·2017
Same author

Is percutaneous medial hamstring myofascial lengthening as anatomically effective and safe as the open procedure?

Journal of children's orthopaedics·2017
Same author

Retinal pigment epithelial cell necroptosis in response to sodium iodate.

Cell death discovery·2016
Same author

OCT angiography and sequential quantitative analysis of type 2 neovascularization after ranibizumab therapy.

Eye (London, England)·2015
Same author

Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration.

Eye (London, England)·2014
Same author

High-dose ranibizumab therapy for vascularized pigment epithelial detachment.

Eye (London, England)·2012
Same journal

Persistent placoid maculopathy: long term outcomes and prognostic factors.

Retina (Philadelphia, Pa.)·2026
Same journal

ANTI-VEGF THERAPY SWITCHING RETINAL DISEASES: Characterizing Clinical Manifestations and Common Involved Genes: ERRATUM.

Retina (Philadelphia, Pa.)·2026
Same journal

THE EFFICACY AND SAFETY OF SUBRETINAL BALANCED SALT SOLUTION INJECTION IN DIABETIC MACULAR EDEMA WITH HARD EXUDATES: ERRATUM.

Retina (Philadelphia, Pa.)·2026
Same journal

EVALUATING CLINICAL OUTCOMES OF AMNIOTIC MEMBRANE COVERAGE COMBINED WITH EARLY VITRECTOMY IN THE MANAGEMENT OF PERFORATING GLOBE INJURIES.

Retina (Philadelphia, Pa.)·2026
Same journal

Mid-Phase Hyperfluorescent Plaques as a biomarker of disease activity in Central Serous Chorioretinopathy: Clinical Course and Treatment Response - MICRoN report number Ten.

Retina (Philadelphia, Pa.)·2026
Same journal

Severe retinal non-perfusion is associated with fewer retinal lesions on ultra-wide field fundus photography in proliferative diabetic retinopathy.

Retina (Philadelphia, Pa.)·2026
See all related articles

The risk of vision loss in the fellow eye of patients with age-related macular degeneration (ARMD) increases with more numerous, larger, and confluent drusen. This risk later shifts towards geographic atrophy (GA).

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Age-Related Macular Degeneration Research

Background:

  • Unilateral neovascular age-related macular degeneration (ARMD) presents a significant risk for fellow eye involvement.
  • Understanding the progression and risk factors for fellow eye disease is crucial for patient management.

Purpose of the Study:

  • To quantify the annual incidence of visual loss in the fellow eyes of patients diagnosed with unilateral neovascular ARMD.
  • To identify specific drusen characteristics that predict the highest risk of visual impairment in the fellow eye.

Main Methods:

  • Prospective follow-up of 101 patients with unilateral exudative ARMD and fellow eye drusen for up to 9 years.
  • Annual assessment of visual acuity, fundus photography, and fluorescein angiography.

Related Experiment Videos

  • Detailed grading of drusen characteristics at study entry.

    • Main Results:

    • The yearly incidence of vision-threatening lesions (choroidal neovascularization [CNV] or geographic atrophy [GA]) ranged from 5% to 14%.
    • The risk of developing CNV peaked around year 4 and subsequently decreased.
    • Increased drusen number, size, and confluence were significantly associated with the development of endpoint lesions.

    Conclusions:

    • An increase in the number, size, and confluence of drusen signals an elevated risk of CNV in patients with ARMD.
    • The risk profile shifts over time, with a later increase in the incidence of GA.